Research & Development
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
2 May 2025 - Blue Earth Therapeutics, a UK-based developer of radiopharmaceutical therapies, on Thursday reported further progress in the development of its radio-hybrid, lutetium-labelled, PSMA targe...
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
2 May 2025 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American:ARMP) announced on Thursday that it has received an additional USD4.65m of non-dilutive funding pursuant to a previously an...
BioArctic receives SEK101.7m in royalties from Q1 Leqembi sales
1 May 2025 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Thursday that its royalties from first-quarter 2025 global sales of Leqembi (lecanemab), developed in partn...
SKNV launches Kefunova Cream for actinic keratosis and superficial basal cell carcinoma
1 May 2025 - SKNV, a Florida-based company involved in dermatologic innovation and custom prescription medications, announced on Wednesday the launch of Kefunova Cream (Fluorouracil 5% / Calcipotriene...
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
1 May 2025 - Ingenium Therapeutics, a South Korea-based clinical-stage biotechnology company advancing allogeneic natural killer (NK) cell therapies, announced on Wednesday that it has received positi...
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF
30 April 2025 - Nuformix plc (LSE: NFX), a pharmaceutical development company focused on unmet needs in fibrosis and oncology, confirmed on Wednesday that the European Medicines Agency's Committe...